Canada markets close in 5 hours 37 minutes

FluroTech Ltd. (TEST.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.01000.0000 (0.00%)
As of 09:30AM EST. Market open.
Full screen
Previous Close0.0100
Open0.0100
Bid0.0050 x 0
Ask0.0100 x 0
Day's Range0.0100 - 0.0100
52 Week Range0.0050 - 0.0750
Volume52,000
Avg. Volume41,025
Market Cap1.207M
Beta (5Y Monthly)-0.83
PE Ratio (TTM)N/A
EPS (TTM)-0.0880
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    FluroTech Ltd. Announces Sale of Shares in FluroTest Diagnostic Systems Ltd. and Option Cancellation

    CALGARY, Alberta, Jan. 03, 2023 (GLOBE NEWSWIRE) -- FluroTech Ltd. (“FluroTech” or the “Company”) (TSXV: TEST) announces that it has entered into a Share Purchase Agreement (“Agreement”) to sell all of the shares of FluroTest Diagnostic Systems Ltd., a wholly-owned subsidiary of the Company, to an arm’s length individual (the “Purchaser”). The Purchaser has agreed to pay total cash consideration of $1.00 in lawful Canadian currency. The completion of the transaction is effective December 31, 202

  • GlobeNewswire

    FluroTech Announces Strategic Exit of COVID-19 Pandemic Testing Business

    CALGARY, Alberta, Nov. 29, 2022 (GLOBE NEWSWIRE) -- FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) (“FluroTech” or the “Company”) announces that it has decided to exit the pandemic and emerging disease industry immediately and halt any further expenditures on development of its Pandemic and Emerging Disease Defense Platform (“PEDDP”). Due to declining rates of COVID-19 and the establishment of testing protocols by various governmental and commercial bodies, the demand for FluroTech’s PEDDP has signi

  • GlobeNewswire

    FluroTech Provides Operational Update: Announces Pause on Further Development of its Pandemic and Emerging Disease Defense Platform

    CALGARY, Alberta, April 08, 2022 (GLOBE NEWSWIRE) -- FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF) (the “Company” or “FluroTech”), announces that it has decided to pause any further expenditures on development of its Pandemic and Emerging Disease Defense Platform (“PEDDP”), initially targeting COVID-19, until it is able to obtain further financing. While management continues to believe that its COVID-19 testing technology will be viable and needed, the Company will require additional financing to c